Zhao Y.-F.,First Affiliated Hospital of the General Hospital of CPLA |
Zhao J.-Y.,First Affiliated Hospital of the General Hospital of CPLA |
Yue H.,First Affiliated Hospital of the General Hospital of CPLA |
Hu K.-S.,General Hospital of CPLA |
And 3 more authors.
Biochemical and Biophysical Research Communications | Year: 2015
Forkhead transcription factors are essential for diverse processes in early embryonic development and organogenesis. As a member of the forkhead family, FOXD1 is required during kidney development and its inactivation results in failure of nephron progenitor cells. However, the role of FOXD1 in carcinogenesis and progression is still limited. Here, we reported that FOXD1 is a potential oncogene in breast cancer. We found that FOXD1 is up-regulated in breast cancer tissues. Depletion of FOXD1 expression decreases the ability of cell proliferation and chemoresistance in MDA-MB-231 cells, whereas overexpression of FOXD1 increases the ability of cell proliferation and chemoresistance in MCF-7 cells. Furthermore, we observed that FOXD1 induces G1 to S phase transition by targeting p27 expression. Our results suggest that FOXD1 may be a potential therapy target for patients with breast cancer. © 2014 Elsevier Inc. All rights reserved.